vs
EXACT SCIENCES CORP（EXAS）与Fidelis Insurance Holdings Ltd（FIHL）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Fidelis Insurance Holdings Ltd的1.3倍（$878.4M vs $651.9M），Fidelis Insurance Holdings Ltd净利率更高（20.0% vs -9.8%，领先29.8%），EXACT SCIENCES CORP同比增速更快（23.1% vs -5.0%），Fidelis Insurance Holdings Ltd自由现金流更多（$154.6M vs $120.4M）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Fidelis Insurance Holdings Ltd是总部位于百慕大的全球特种保险与再保险服务商，提供财产、意外伤害、海事、航空等领域的定制化风险保障方案，服务范围覆盖北美、欧洲等地区的企业及机构客户。
EXAS vs FIHL — 直观对比
营收规模更大
EXAS
是对方的1.3倍
$651.9M
营收增速更快
EXAS
高出28.1%
-5.0%
净利率更高
FIHL
高出29.8%
-9.8%
自由现金流更多
FIHL
多$34.2M
$120.4M
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $651.9M |
| 净利润 | $-86.0M | $130.5M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 24.7% |
| 净利率 | -9.8% | 20.0% |
| 营收同比 | 23.1% | -5.0% |
| 净利润同比 | 90.1% | 29.7% |
| 每股收益（稀释后） | $-0.45 | $1.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASFIHL
| Q4 25 | $878.4M | — | ||
| Q3 25 | $850.7M | $651.9M | ||
| Q2 25 | $811.1M | $589.3M | ||
| Q1 25 | $706.8M | $658.4M | ||
| Q4 24 | $713.4M | — | ||
| Q3 24 | $708.7M | $686.1M | ||
| Q2 24 | $699.3M | $540.1M | ||
| Q1 24 | $637.5M | $520.0M |
净利润EXASFIHL
| Q4 25 | $-86.0M | — | ||
| Q3 25 | $-19.6M | $130.5M | ||
| Q2 25 | $-1.2M | $19.7M | ||
| Q1 25 | $-101.2M | $-42.5M | ||
| Q4 24 | $-864.6M | — | ||
| Q3 24 | $-38.2M | $100.6M | ||
| Q2 24 | $-15.8M | $53.7M | ||
| Q1 24 | $-110.2M | $81.2M |
毛利率EXASFIHL
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASFIHL
| Q4 25 | -9.4% | — | ||
| Q3 25 | -3.0% | 24.7% | ||
| Q2 25 | -0.3% | 3.8% | ||
| Q1 25 | -13.6% | -7.6% | ||
| Q4 24 | -122.8% | — | ||
| Q3 24 | -5.6% | 17.2% | ||
| Q2 24 | -3.8% | 11.6% | ||
| Q1 24 | -16.7% | 18.3% |
净利率EXASFIHL
| Q4 25 | -9.8% | — | ||
| Q3 25 | -2.3% | 20.0% | ||
| Q2 25 | -0.1% | 3.3% | ||
| Q1 25 | -14.3% | -6.5% | ||
| Q4 24 | -121.2% | — | ||
| Q3 24 | -5.4% | 14.7% | ||
| Q2 24 | -2.3% | 9.9% | ||
| Q1 24 | -17.3% | 15.6% |
每股收益（稀释后）EXASFIHL
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $-0.10 | $1.24 | ||
| Q2 25 | $-0.01 | $0.18 | ||
| Q1 25 | $-0.54 | $-0.38 | ||
| Q4 24 | $-4.69 | — | ||
| Q3 24 | $-0.21 | $0.88 | ||
| Q2 24 | $-0.09 | $0.46 | ||
| Q1 24 | $-0.60 | $0.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $892.5M |
| 总债务越低越好 | — | $842.9M |
| 股东权益账面价值 | $2.4B | $2.4B |
| 总资产 | $5.9B | $12.5B |
| 负债/权益比越低杠杆越低 | — | 0.35× |
8季度趋势，按日历期对齐
现金及短期投资EXASFIHL
| Q4 25 | $964.7M | — | ||
| Q3 25 | $1.0B | $892.5M | ||
| Q2 25 | $858.4M | $919.4M | ||
| Q1 25 | $786.2M | $733.4M | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | $806.8M | ||
| Q2 24 | $946.8M | $628.6M | ||
| Q1 24 | $652.1M | $671.7M |
总债务EXASFIHL
| Q4 25 | — | — | ||
| Q3 25 | — | $842.9M | ||
| Q2 25 | — | $842.6M | ||
| Q1 25 | — | $449.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $448.8M | ||
| Q2 24 | — | $448.6M | ||
| Q1 24 | — | $448.4M |
股东权益EXASFIHL
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.5B | $2.4B | ||
| Q2 25 | $2.5B | $2.3B | ||
| Q1 25 | $2.4B | $2.4B | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $3.2B | $2.6B | ||
| Q2 24 | $3.2B | $2.5B | ||
| Q1 24 | $3.1B | $2.5B |
总资产EXASFIHL
| Q4 25 | $5.9B | — | ||
| Q3 25 | $5.9B | $12.5B | ||
| Q2 25 | $5.8B | $13.0B | ||
| Q1 25 | $5.7B | $12.8B | ||
| Q4 24 | $5.9B | — | ||
| Q3 24 | $6.7B | $11.7B | ||
| Q2 24 | $6.7B | $11.9B | ||
| Q1 24 | $6.4B | $11.3B |
负债/权益比EXASFIHL
| Q4 25 | — | — | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.36× | ||
| Q1 25 | — | 0.19× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.17× | ||
| Q2 24 | — | 0.18× | ||
| Q1 24 | — | 0.18× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $155.2M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $154.6M |
| 自由现金流率自由现金流/营收 | 13.7% | 23.7% |
| 资本支出强度资本支出/营收 | 3.6% | 0.1% |
| 现金转化率经营现金流/净利润 | — | 1.19× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $-320.9M |
8季度趋势，按日历期对齐
经营现金流EXASFIHL
| Q4 25 | $151.7M | — | ||
| Q3 25 | $219.9M | $155.2M | ||
| Q2 25 | $89.0M | $-359.2M | ||
| Q1 25 | $30.8M | $-433.1M | ||
| Q4 24 | $47.1M | — | ||
| Q3 24 | $138.7M | $318.9M | ||
| Q2 24 | $107.1M | $208.5M | ||
| Q1 24 | $-82.3M | $-35.3M |
自由现金流EXASFIHL
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | $154.6M | ||
| Q2 25 | $46.7M | $-359.3M | ||
| Q1 25 | $-365.0K | $-433.4M | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | $317.2M | ||
| Q2 24 | $71.2M | $206.6M | ||
| Q1 24 | $-120.0M | $-35.6M |
自由现金流率EXASFIHL
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | 23.7% | ||
| Q2 25 | 5.8% | -61.0% | ||
| Q1 25 | -0.1% | -65.8% | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | 46.2% | ||
| Q2 24 | 10.2% | 38.3% | ||
| Q1 24 | -18.8% | -6.8% |
资本支出强度EXASFIHL
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | 0.1% | ||
| Q2 25 | 5.2% | 0.0% | ||
| Q1 25 | 4.4% | 0.0% | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | 0.2% | ||
| Q2 24 | 5.1% | 0.4% | ||
| Q1 24 | 5.9% | 0.1% |
现金转化率EXASFIHL
| Q4 25 | — | — | ||
| Q3 25 | — | 1.19× | ||
| Q2 25 | — | -18.23× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.17× | ||
| Q2 24 | — | 3.88× | ||
| Q1 24 | — | -0.43× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
FIHL
暂无分部数据
